Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72) were treated with docetaxel 100 mg m(-2) administered as a 1-h infusion every 3 weeks. Of 29 evaluable...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1998-11, Vol.78 (10), p.1342-1345
Main Authors: de Wit, R, Kruit, WHJ, Stoter, G, de Boer, M, Kerger, J, Verweij, J
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Antineoplastic Agents, Phytogenic - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - pathology
Chemotherapy
clinical-oncology
Disease Progression
Docetaxel
Drug Administration Schedule
Drug Resistance
Edema - chemically induced
Epidemiology
Female
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Molecular Medicine
Neutropenia - chemically induced
Oncology
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel - analogs & derivatives
Paclitaxel - therapeutic use
Pharmacology. Drug treatments
Taxoids
Treatment Outcome
Urologic Neoplasms - drug therapy
Urologic Neoplasms - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72) were treated with docetaxel 100 mg m(-2) administered as a 1-h infusion every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 31%. The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications (5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in urothelial cell cancer, and should be further tested in combination chemotherapy.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1998.681